Oruka Therapeutics, Inc. (ORKA)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$101.41+1.87%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · ORKA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -19.5% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 66 industry peers
ORKA — litigation filed
Dated 2026-10-26
Other Events. On October 26, 2026, Oruka announced Week 16 results from its Phase 2b EVERLAST-B clinical trial of ORKA-001 in patients with moderate-to-severe PsO. EVERLAST-B Phase 2b Key 16-Week Results EVERLAST-B is a randomized, double-blind, placebo-controlled Phase 2b clinical trial evaluating the safety, efficacy and pharmacokinetics of ORKA-001 in patients with moderate-to-severe PsO. The trial enrolled 187 patients randomized 1:1:1:1 to receive 37.5 mg of ORKA-001 at Week 0 (“Low Dose…
Why it matters: These results will show whether ORKA-002 can also treat psoriasis. They add a test of Oruka's second lead program.
Watch forThe 1Q 2027 update reports Week 16 results with clear gains on the trial's main skin response measures versus placebo.
Also watch forThe update shows no clear benefit over placebo, or Oruka delays the results beyond 1Q 2027.
Why it matters: These results test whether ORKA-001 keeps its strong skin-clearance results over time. They also test the case for once- or twice-yearly dosing.
Watch forThe December 2026 update shows PASI 100 responses stay near the Week 16 rate of 63.5%, with no new safety concern.
Also watch forThe update shows a clear drop in PASI 100 responses from 63.5%, or reports a new serious safety concern.
Why it matters: The Phase 3 plan is the next step after positive Phase 2 results. A clear start date would keep the program on its stated path.
Supportive ifOruka reports regulator talks are complete and starts ORKA-001 Phase 3 trials in the first half of 2027.
Worry ifOruka delays the Phase 3 start past the first half of 2027 or reports that regulator talks require more studies.
Why it matters: Oruka reported $1.1 billion in cash and said it could fund work through an ORKA-001 BLA filing. Future cash updates can test that claim.
Worry ifA later company update says its cash will last through an ORKA-001 BLA filing and ORKA-002 development.
Less concerning ifA later update says cash will not last through the planned ORKA-001 BLA filing, or says more funding is needed.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$193 on $10,000 · ±1.9% | How much price usually moves either way. |
| Bad day | $554 loss on $10,000 · 5.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,639 loss on $10,000 · 36.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.